Genedrive PLC Notice of Results (8079E)

TIDMGDR

RNS Number : 8079E

Genedrive PLC

14 February 2018

For release: 14 February 2018

genedrive plc ("genedrive" or the "Company")

Notice of Interim Results

genedrive plc, (AIM: GDR), the near patient molecular diagnostics company, will be announcing its interim results for the six months ending 31 December 2017 on Tuesday 20 March.

David Budd, Chief Executive Officer, and Matthew Fowler, Chief Financial Officer, will host a presentation and simultaneous live conference call for analysts, followed by a Q&A session, at 9:30am on the day of the results. The presentation will be held at 85 Gresham Street, London, EC2R 7HE.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO [phone]

Matthew Fowler: CFO

Peel Hunt LLP

James Steel [phone]

Oliver Jackson

Consilium Strategic Communications

Chris Gardner [phone]

Matthew Neal

Laura Thornton

[e-mail]

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) platform and MTB/RIF assay has been launched in India and a Genedrive(R) HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and Asia Pacific regions.

Further details can be found at: www.genedriveplc.com and www.genedrive.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORTIMMTMBMBMRP

(END) Dow Jones Newswires

February 14, 2018 02:00 ET (07:00 GMT)